Literature DB >> 2643037

Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.

A Walan1, J P Bader, M Classen, C B Lamers, D W Piper, K Rutgersson, S Eriksson.   

Abstract

Omeprazole blocks the action of H+,K+-ATPase in the gastric mucosa and thus inhibits the secretion of hydrochloric acid. We conducted a double-blind multicenter study (45 centers in 13 countries) of 602 patients with benign gastric or prepyloric ulcers to compare the effectiveness of omeprazole (20 mg once daily, 203 patients, or 40 mg once daily, 194 patients) and ranitidine, an H2-receptor antagonist (150 mg twice daily, 205 patients) in promoting ulcer healing and to evaluate the pattern of ulcer relapse during a six-month follow-up. Healing occurred at four weeks in 80 percent of the patients receiving 40 mg of omeprazole, 69 percent of those receiving 20 mg of omeprazole, 69 percent of those receiving ranitidine. At eight weeks, the corresponding figures were 96, 89, and 85 percent. A multivariate analysis of ulcer healing showed that at four weeks the ulcers of significantly more patients receiving omeprazole had healed as compared with patients receiving ranitidine (omeprazole, 40 mg, vs. ranitidine, P less than 0.0005; omeprazole, 20 mg, vs. ranitidine, P = 0.01). At eight weeks, the 40-mg dose of omeprazole was significantly more effective than ranitidine (P = 0.001) or the 20-mg dose of omeprazole (P = 0.03). Ulcer symptoms were relieved faster with omeprazole. In 68 patients receiving concurrent nonsteroidal antiinflammatory drugs, the healing rates at four weeks were 81 percent in the group receiving 40 mg of omeprazole, 61 percent in the group receiving 20 mg, and 32 percent in the group receiving ranitidine; at eight weeks, the corresponding figures were 95, 82, and 53 percent. During the six-month follow-up period (without treatment), significantly more patients in the omeprazole groups were free of symptoms and ulcers than in the ranitidine group. We conclude that in the dose used, omeprazole is superior to ranitidine in the treatment of benign gastric ulcers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643037     DOI: 10.1056/NEJM198901123200201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  88 in total

1.  Pharmacokinetic study of omeprazole in elderly healthy volunteers.

Authors:  S Landahl; T Andersson; M Larsson; B Lernfeldt; P Lundborg; C G Regårdh; E Sixt; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Gastrointestinal complications of nonsteroidal anti-inflammatory drugs.

Authors:  R R Babb
Journal:  West J Med       Date:  1992-10

3.  Nonsteroidal anti-inflammatory drugs and ulcers.

Authors:  A H Soll
Journal:  West J Med       Date:  1992-10

4.  Influence of acid secretory status on absorption of omeprazole from enteric coated granules.

Authors:  T Andersson; R Bergstrand; C Cederberg
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

5.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Omeprazole in gastric and duodenal ulcers.

Authors:  V Savarino; G S Mela; G Celle
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

Review 7.  Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions.

Authors:  R I Russell
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

8.  Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study.

Authors:  Viktorija Erdeljic; Igor Francetic; Viola Macolic Sarinic; Marinko Bilusic; Ksenija Makar Ausperger; Mirjana Huic; Iveta Mercep
Journal:  Pharm World Sci       Date:  2006-11-17

Review 9.  Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use.

Authors:  J Cashman; G McAnulty
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

10.  Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.

Authors:  T Andersson; K Andrén; C Cederberg; P O Lagerström; P Lundborg; I Skånberg
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.